Max CEO’s Ongoing Commitment to Treatment Access Solutions Recognized by iCMLf ERSAP Prize

Max CEO’s Ongoing Commitment to Treatment Access Solutions Recognized by iCMLf ERSAP Prize

We’re often reminded of why we put an effort in supporting people facing cancer – whether it comes through a patient story or through an organization’s investment in our work. This week, we humbly received another reminder: on Friday, May 22, the International Chronic Myeloid Leukemia (CML) Foundation awarded our CEO Pat Garcia-Gonzalez with the inaugural ERSAP (Emerging Region Support and Partnership) Prize. The iCMLf Directors and Scientific Advisors selected Pat because of her continued commitment, and The Max Foundation’s aim, to help people face cancer with dignity and hope.

Tim Hughes, iCMLf Chair, stated, “Pat strongly believes that people living with CML have the right to access the best possible treatment and support, wherever they live. This is why she has been so determined to make new drugs for CML fully available to patients in emerging economic regions through access programs, education and global advocacy efforts.”

“I am honored to receive the first ever ERSAP Prize and thank our partners at the International CML Foundation for their recognition.” Pat stated. “I take this award as an opportunity to reflect on how providing access to life-saving treatments to people around the world makes our global community stronger and a more just place to live. There are still so many people around the world who deserve advocacy and support and we carry out our work on their behalf. This award reignites our passion for finding innovative solutions to help people face cancer with dignity and hope.”

You can read further details about why Pat was selected for the ERSAP Prize on the iCMLf announcement.blogpost384_1

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • 20 Years of Gratitude

    20 Years of Gratitude

    This Thanksgiving holiday, we are grateful for 20 years of support from our global community.
    Thanks to each and every one of you for all you have done to bring dignity and hope to people facing cancer around the world.

    Click through our photo gallery to see some of our favorite moments of the year so far. Happy Thanksgiving!

  • Keeping Our Cool: Developing a Cold-Chain to Further Treatment Access

    Keeping Our Cool: Developing a Cold-Chain to Further Treatment Access

    A “cold-chain” product must remain within a specific temperature range at all times. On days- or weeks-long international shipments, it’s especially challenging (and expensive) to keep medicine at a constant temperature. Despite the inherent challenges, adding cold-chain capability is well worth the effort for the patients we support. By doing so, The Max Foundation will be able to better meet the needs of patients who are unresponsive to tablet therapies.

  • Colors of Hope in The Lancet Oncology

    Colors of Hope in The Lancet Oncology

    At The Max Foundation, increasing global access to treatment for people around the world living with cancer is a core element of our mission. But access to treatment is only one piece in helping all people facing cancer live with dignity and hope. Fostering care and support for patients processing the hardships of cancer is essential.